Ellsworth Advisors LLC Takes Position in Harrow, Inc. $HROW

Ellsworth Advisors LLC acquired a new position in shares of Harrow, Inc. (NASDAQ:HROW) in the fourth quarter, Holdings Channel.com reports. The fund acquired 18,909 shares of the company’s stock, valued at approximately $917,000.

Other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in Harrow during the second quarter valued at about $48,000. State of Alaska Department of Revenue purchased a new position in shares of Harrow during the 3rd quarter valued at about $83,000. Tower Research Capital LLC TRC lifted its position in Harrow by 345.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after buying an additional 2,615 shares during the last quarter. Larson Financial Group LLC boosted its stake in Harrow by 848.2% in the third quarter. Larson Financial Group LLC now owns 2,162 shares of the company’s stock worth $104,000 after buying an additional 1,934 shares in the last quarter. Finally, Strs Ohio bought a new position in Harrow during the first quarter valued at approximately $149,000. Institutional investors own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. BTIG Research restated a “buy” rating and set a $63.00 price target on shares of Harrow in a research report on Wednesday, March 18th. Cantor Fitzgerald reduced their price objective on Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. William Blair reissued an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Finally, HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Harrow in a report on Thursday, March 19th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $71.14.

Harrow Price Performance

HROW stock opened at $35.43 on Thursday. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -208.40 and a beta of 0.05. The firm’s 50-day moving average price is $42.46 and its two-hundred day moving average price is $43.29. The company has a current ratio of 2.20, a quick ratio of 2.06 and a debt-to-equity ratio of 4.67. Harrow, Inc. has a 12-month low of $20.85 and a 12-month high of $54.85.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.